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Abstract
Background and purpose Increased tumour hypoxia is asso-
ciated with a worse overall survival in patients with head and
neck squamous cell carcinoma (HNSCC). The aims of this
study were to evaluate treatment-associated changes in
[18F]HX4-PET, hypoxia-related blood biomarkers, and their
interdependence.
Material and methods [18F]HX4-PET/CTscans of 20 patients
with HNSCC were acquired at baseline and after ±20Gy of
radiotherapy. Within the gross-tumour-volumes (GTV; prima-
ry and lymph nodes), mean and maximum standardized up-
take values, the hypoxic fraction (HF) and volume (HV) were
calculated. Also, the changes in spatial uptake pattern were
evaluated using [18F]HX4-PET/CT imaging. For all patients,
the plasma concentration of CAIX, osteopontin and VEGF
was assessed.
Results At baseline, tumour hypoxia was detected in 69 %
(22/32) of the GTVs. During therapy, we observed a signifi-
cant decrease in all image parameters. The HF decreased from
21.7±19.8 % (baseline) to 3.6± 10.0 % (during treatment;
P<0.001). Only two patients had a HV>1 cm3 during treat-
ment, which was located for >98 % within the baseline HV.
During treatment, no significant changes in plasma CAIX or
VEGF were observed, while osteopontin was increased.
Conclusions [18F]HX4-PET/CT imaging allows monitoring
changes in hypoxia during (chemo)radiotherapy whereas the
blood biomarkers were not able to detect a treatment-
associated decrease in hypoxia.
Keywords Hypoxia . PET . CAIX . Osteopontin . VEGF
Introduction
Tumour cell hypoxia is known to promote resistance to cancer
treatment, to increase tumour aggressiveness, and to be a
prognostic factor for survival [1]. Non-invasive imaging of
tumour hypoxia by means of positron emission tomography
(PET) has been shown to predict loco-regional control and
survival, and may be used to select patients for additional
anti-hypoxia therapy [2–4]. In addition, PET imaging can be
used to monitor the response to treatment. Previous studies
using the hypoxia PET tracer [18F]FMISO and the metabolic
PET tracer [18F]FDG observed that the uptake changes (early)
during (chemo)radiotherapy had a higher predictive value
than pre-treatment measurements [3, 5]. Previously,
Overgaard [6] showed that the modification of hypoxia during
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radiotherapy results in better loco-regional control and surviv-
al in patients with a squamous cell carcinoma of the head and
neck (HNSCC). However, stratifying patients undergoing
ARCON (accelerated radiotherapy with carbogen and nicotin-
amide) based on their pre-therapeutic hypoxic status
(pimonidazole staining) demonstrated that the benefit in
loco-regional control was specifically observed for patients
with initial tumour hypoxia before the start of treatment [7,
8]. The pimonidazole staining of a biopsy, however, can only
provide information about local hypoxia before the start of
treatment. Non-invasive hypoxia PET imaging, on the other
hand, provides an opportunity to perform repeated tumour
hypoxia measurements in 3-dimensions. Therefore hypoxia
PET measurements may be used to select patients likely to
have a benefit from additional anti-hypoxia therapy.
One of the hypoxia PET tracers to visualize and quan-
tify tumour hypoxia is the 2-nitroimidazole3-[18F]fluoro-
2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-
1-yl)propan-1-ol, [18F]HX4. In previous pre-clinical stud-
ies [18F]HX4 was validated as a hypoxia tracer, and the
repeatability of the tracer uptake was assessed [9, 10]. In
addition, in patients with non-small cell lung cancer
(NSCLC), [18F]HX4 showed promising results and was
shown to provide additional value to the metabolic PET
tracer [18F]FDG [11, 12]. In this paper, we will investigate
the potential of this tracer to detect treatment-associated
changes in hypoxic tumour status in patients with
HNSCC.
Another method to obtain information on tumour
hypoxia may be the measurement of hypoxia-related
proteins or enzymes in plasma. Potential relevant hyp-
oxia markers are plasma osteopontin, carbonic
anhydrase IX (CAIX), and vascular endothelial growth
factor (VEGF). Osteopontin is activated under hypoxic
conditions and is inversely correlated with the PO2 val-
ue of the tumour [13]. In addition, plasma osteopontin
is a significant predictor for the response to radiothera-
py in patients with head and neck cancer [14]. CAIX
expression is upregulated under the influence of tumour
hypoxia. Also, in patients with NSCLC, a high level of
plasma CAIX was associated with a shorter overall sur-
vival [15]. Last, hypoxia activates hypoxia inducible
factor (HIF-1), which induces a high expression of
VEGF, the primary cytokine related to angiogenesis.
VEGF may, therefore, serve as an indirect marker of
tumour hypoxia. These three markers might have the
potential to stratify patients based on their hypoxic tu-
mour status.
The aims of this study were to evaluate the changes in
hypoxia during treatment in patients with HNSCC, the spatial
stability of the uptake pattern, and the presence of plasma




Between January 2012 and October 2014, we included 20
patients in this imaging study. Patient, tumour, and treatment
characteristics are shown in Table 1. The study was approved
by the Ethical Review Committee of Maastricht University
Medical Centre and registered on clinicaltrial.gov
(NCT01347281). All patients provided written informed con-
sent before study entry.
PET/CT imaging
[18F]HX4 was produced as described in previous publications
[9, 16–18]. After intravenous administration of an average
(±SD) dose of 378± 84 MBq [18F]HX4, PET/CT imaging
was performed at 1.5, 3, and 4 h post-injection (p.i.) for 15,
15, and 20 min, respectively, for a single bed position centred
around the primary tumour. After ten patients, an interim anal-
ysis showed highest contrast at the imaging time-point at 4 h
p.i., and this was used from then onwards.
[18F]HX4 PET/CT scans were acquired before the start of
external beam radiotherapy and during the radiation treatment;
after an average (±SD) dose of 21±2 Gy using a Biograph 40
PET/CT scanner (Siemens Healthcare, Erlangen, Germany).
Scatter and attenuation corrections were applied, PET images
were reconstructed using OSEM 2D (Ordered Subset
Expectation Maximization, four iterations, eight subsets) and
a Gaussian filter of 5 mm. Imaging was performed in radio-
therapy position, with the patient positioned on a flat table top
using an immobilization mask and a movable laser alignment
system.
Image analysis
The gross tumour volume of the primary lesion (GTVprim) and
involved lymph nodes (GTVln), were delineated on the
[18F]FDG PET/CT, used for radiotherapy planning purposes,
by two experienced radiation oncologists in consensus. These
contours were copied to the [18F]HX4 PET scan at baseline
and during treatment by rigid registration. Maximum and
mean standardized uptake values (SUVmax and SUVmean),
were determined within the GTVs. In addition, the maximum
tumour-to-muscle ratio (TMRmax), was calculated, defined as
the SUVmax in the tumour divided by the SUVmean in the
trapezius muscles (Supplementary Fig. 1). The hypoxic frac-
tion (HF) and hypoxic volume (HV) were defined as the frac-
tion or volume of the GTV with a TMR larger than 1.4.
To evaluate the spatial location of the [18F]HX4 PET up-
take at baseline and during treatment, the [18F]HX4 PET/CT
acquired during radiotherapy was rigidly registered to the
baseline [18F]HX4 PET/CT. The rigid transformation was
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determined by the registration of the CT scans; subsequently,
the same transformation was applied to the PET scans and
GTV to co-register the images. A visual and voxel-wise com-
parison of the [18F]HX4 uptake before and during radiothera-
py was performed to compare spatial uptake patterns for both
GTVprim and GTVln.
Blood biomarker analysis
For all patients, blood samples were collected before and dur-
ing (chemo)radiotherapy on the day of the [18F]HX4 PET/CT
scan. All blood biomarkers were measured in EDTA plasma.
Samples were analysed simultaneously in a certified laborato-
ry, using commercially available kits. CAIX was measured by
a sandwich-type immunoassay that uses a mouse
monocolonal capture antibody (V10) and a biotinylated
mouse monocolonal antibody (M75) as detector (Nuclea
Diagnost ic Laborator ies LLC, Cambridge, MA).
Osteopontin and VEGF were measured by an ELISA method.
A monoclonal antibody specific for osteopontin/VEGF was
pre-coated onto the microplate and an enzyme-lined polyclon-
al antibody specific for osteopontin /VEGF was used as de-
tector (R&D Systems (Minneapolis, MN).
To compare the plasma hypoxia markers with the
[18F]HX4 uptake in the GTVprim and GTVln, we hypothesize
that these markers reflect the uptake in all lesions within one
patient. Therefore, the image parameters of multiple GTVs
were combined, providing one SUVmax and TMRmax (the
maximum of the present lesions). The hypoxic volumes were
summed and for the SUVmean a weighted average was calcu-
lated using:
weighted SUVmean
¼ SUVmean GTVprim * GTVprim þ SUVmean GTVln * GTVln
GTVprim þ GTVln
Statistical analysis
For all parameters, mean ± 1 standard deviation (SD) are re-
ported. Non-parametric tests were used to determine signifi-
cant differences in image and blood plasma parameters
(Wilcoxon signed rank test) and to evaluate correlations be-
tween imaging parameters and blood parameters (Spearman’s
correlation coefficient; Rs). Linear regressions were per-
formed to quantify the voxel-wise comparison, and a
Pearson correlation coefficient (Rp) was calculated. A p-val-
ue<0.05 was assumed to be statistically significant.
Results
In this study we analysed the [18F]HX4 uptake of 20 patients
with HNSCC before the start of radiotherapy. For 3/20 pa-
tients the [18F]HX4 PET scan during radiotherapy was not
performed due to the patient’s preference or health status.
Eleven patients had involvement of the lymph nodes
(GTVln), which were separately analysed from the primary
lesion (GTVprim). The average lesion sizes for GTVprim was
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17.6±12.3 cm3 (range: 2.4–46.6 cm3) and for GTVln 22.6
±30.5 (range: 1.3–105.2 cm3).
[18F]HX4 PETuptake at baseline
In the first ten patients, [18F]HX4 PET/CT imaging was ac-
quired at 1.5, 3, and 4 h p.i. In their lesions (10 GTVprim and 9
GTVln) we observed a significant increase in the TMRmax
from 1.5 h (1.5±0.3) to 3 h p.i. (1.7±0.4; P<0.01), and from
3 to 4 h p.i. (1.8±0.6; P=0.02) (Fig. 1). Therefore, [18F]HX4
PET/CT imaging at 4 h p.i. was selected as the standard and
applied as the single imaging timepoint for the remaining
patients.
At baseline we observed tumour hypoxia (TMR>1.4 at 4 h
p.i.) in 69 % (22/32) of the GTVprim and GTVln. For all le-
sions, we observed an average SUVmean, SUVmax and
TMRmax of 0.8 ± 0.2, 1.3 ± 0.5 and 1.7 ± 0.5, respectively.
The average HF and HV were 16±20 % and 4.9±9.6 cm3.
All these image parameters were significantly correlated to the
volume of the lesion, SUVmean (Rs=0.38, p=0.03), SUVmax
(Rs = 0.57, p< 0.001), TMRmax (Rs = 0.75, p< 0.001), HF
(Rs=0.63, p<0.001) and HV (Rs=0.74, p<0.001).
[18F]HX4 PETuptake during treatment
We observed a significant correlation between the image pa-
rameters measured at baseline and during treatment: SUVmean
(Rs=0.66, P<0.001), SUVmax (Rs=0.63, P<0.001), TBRmax
(Rs=0.57, P<0.01), HF (Rs=0.56, P<0.01), HV(R=0.52,
P<0.01). Taking into account the hypoxic lesions (GTVprim
and GTVln), with a [
18F]HX4 PET/CT scan at baseline and
during treatment (N=17), we observed a significant decrease
in all image-derived parameters during therapy (Table 2;
Fig. 2). This decrease was independent of the given treatment
(Supplementary Table 1). Of the 17 hypoxic lesions at base-
line, only seven had a HF>0 during treatment. In the other ten
lesions hypoxia as measured by [18F]HX4 PET imaging had
disappeared.
Only one non-hypoxic lesion (TBR=1.37, HF=0) at base-
line, changed its hypoxic status during treatment. However,
The TBRmax increased only from 1.37 at baseline to 1.43
during treatment resulting in a small HF and HV during treat-
ment of 0.4 % and 0.2 cm3, respectively.
Spatial stability of [18F]HX4 PET uptake
To perform an analysis of the spatial [18F]HX4 uptake, a sig-
nificant tracer uptake in both [18F]HX4 PET/CT scans was
necessary. Only two lesions (both GTVln) had a HV larger
than 1 cm3 during treatment (2.9 and 10.1 cm3). These
GTVln were selected for the voxel-wise analysis of the
[18F]HX4 uptake within the GTV, resulting in a Pearson’s
correlation coefficient of 0.63 and 0.85, respectively. The
HV during treatment largely overlapped within the HV at
baseline (98 and 100 %, respectively; Fig. 3).
Blood biomarkers
At baseline (N=20) we measured an average concentration of
57±26 ng/ml osteopontin, 190±120 pg/ml CAIX, and 85
±67 pg/ml VEGF. There was no inter-correlation between
t h e d i f f e r e n t p l a s m a p a r a m e t e r s . D u r i n g
(chemo)radiotherapy (N=17), a non-significant decrease in
CAIX (173±97 pg/ml; P=0.45) and VEGF (75±67 pg/ml;
P=0.74) was observed, whereas the increase in osteopontin
was significant (65 ± 31 pg/ml; P = 0.04; Supplementary
Fig. 2).
Relationship blood biomarkers and [18F]HX4 PET
At baseline none of the blood biomarkers (CAIX, VEGF, and
osteopontin) showed a correlation with any of the [18F]HX4
PET image parameters. Also, no correlation between the
blood biomarkers and the tumor volume was observed.
During treatment, only the osteopontin concentration was
Fig. 1 [18F]HX4 PET/CT scans of a patient with a T2N2bMx squamous
cell carcinoma of the oropharynx, scanned at 1.5 h (a), 3 h (b), and 4 h p.i.
(c). d: The tumour to muscle ratio (TMRmax) for all patients. Shown are
the gross tumour volumes of the primary lesions (GTVprim) and the
metastatic lymph nodes (GTVln), which increased significantly (1.5 h
vs 3 h: p < 0.01, 3 h vs 4 h: p= 0.02)
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weakly correlated with the SUVmean on the [
18F]HX4 PET
(Rs=0.52, P=0.03; Supplementary Fig. 2).
Discussion
In this study we evaluated tumour hypoxia with [18F]HX4
PET in patients with HNSCC before the start of
(chemo)radiotherapy and during treatment, with the aim to
monitor treatment response and evaluate the spatial variability
of the [18F]HX4 uptake. In addition, the concentration of
blood hypoxia markers (osteopontin, CAIX, and VEGF)
was evaluated at baseline and during treatment. Last, the in-
terdependence between hypoxia PET imaging and hypoxia-
related blood biomarkers was investigated.
Before the start of (chemo)radiotherapy, we observed
tumour hypoxia in the majority of primary HNSCC and
metastatic lymph nodes. However, in most of these le-
sions, hypoxia disappeared during the course of treatment,
regardless of the chosen treatment; radiotherapy alone or
in combination with cisplatin or cetuximab. The decrease
of hypoxia during treatment has been described in several
studies [3, 19–21]. Lee et al. [19] showed with
[18F]FMISO PET imaging a decrease in detectable tumour
hypoxia from 90 % (18/20 patients) at baseline to 11 %
(2/18) after 4 weeks of chemoradiotherapy. In addition,
Servagi-Vernat et al. [20] observed a decrease of the
[18F]FAZA PET uptake (SUVmax and HF) in all patients
during chemoradiotherapy, which was recently confirmed
by Bollineni et al. [21]. From our current results and the
previous literature, we can conclude that in patients with
HNSCC, hypoxia decreases during treatment, indicating
tumour reoxygenation. Nevertheless, also a decrease in
cell number, changes in vasculature, or perfusion could
contribute to the altered hypoxia PET uptake.
Additionally, our results show that the patients with a high
uptake at baseline have the highest chance of persistent hyp-
oxia during treatment. These patients may benefit most from
anti-hypoxia therapy during the entire course of treatment. For
the other cases, the addition of anti-hypoxia therapy will prob-
ably have the largest therapeutic effect when given prior to, or
during the first weeks of treatment. Since after this period, the
Table 2 [18F]HX4 PET/CT
parameters at baseline and during
therapy. Shown are the mean,
standard deviation, range, and the
percentage difference
Baseline During treatment Difference [%] Significance (P-value)

























Shown are the baseline hypoxic lesions (GTVprim and GTVln), with an [
18 F]HX4 PET/CT scan at baseline and
during treatment (total lesions N= 17). The provided significance is based on the Wilcoxon signed rank test
Fig. 2 [18F]HX4 PET/CT scan of a patient with a T3N2bMx squamous
cell carcinoma of the hypopharynx treated with cisplatin chemo-radiation.
a: Scan with hypoxic primary tumour at baseline, b: decreased level of
hypoxia during treatment and c: Calculated hypoxic fraction (HF) of all
primary tumours and lymph nodes before and during treatment,
significant decrease (p< 0.001)
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amount of tumour hypoxia is low. [18F]HX4 PET imaging has
already shown its potential to monitor the response to the anti-
hypoxia treatment with TH-302 [22]. The ability to monitor
the response to anti-hypoxia treatment with non-invasive im-
aging provides the potential to adapt the anti-hypoxia treat-
ment based on the (changing) lesion characteristics.
Another frequently discussed method to target resistant tu-
mour volumes is by giving a radiation boost. Previous studies
have shown that it is technically feasible to provide a radio-
therapy boost to hypoxic or metabolically active tumour
subvolumes, defined on PET [4, 23–25]. For this purpose,
information on the spatial repeatability of the hypoxia PET
uptake and its stability during treatment is essential. In our
current data-set only two lesions showed a significant amount
of tumour hypoxia during treatment, with a spatially stable
localization in comparison to the baseline scan. Where
Bittner et al. [26] reported a geographically stable localization
of the [18F]FMISO PET uptake during chemoradiotherapy,
Nehmeh et al. [27], Lin et al. [27], and Servagi-Vernat et al.
[20] reported changes in the distribution of hypoxia during
treatment, and, therefore, adaptive radiotherapy based on se-
rial hypoxia PET imaging was recommended.
Serial hypoxia PET imaging during treatment may provide
additional information for response prediction. In a preclinical
setting, micro-environmental parameters (hypoxia, perfusion)
during treatment had a better potential to predict outcome after
radiotherapy [28]. This finding was confirmed in a clinical
study by Zips et al. [3] in 25 patients with HNSCC. The
authors found a significant correlation between [18F]FMISO-
PET imaging before and during chemoradiotherapy and local
progression free survival, and tumour hypoxia during treat-
ment was of higher prognostic relevance. In our study, accrual
is ongoing and the assessment of hypoxia in relationship to
outcome will be performed as data have matured.
We hypothesized that blood biomarkers could also be
used to monitor treatment response, because previous
studies have showed that blood biomarkers have the
potential to predict response to treatment [29]. For exam-
ple, a high concentration of plasma osteopontin was relat-
ed to a higher amount of locoregional tumour failure in
patients with HNSCC [14]. The blood biomarkers CAIX
and VEGF, showed no significant changes during treat-
ment and the osteopontin concentration was increased,
while hypoxia PET imaging showed a clear reduction of
the uptake in all patients. These results might be ex-
plained by the patient cohort. When comparing the plasma
osteopontin levels of the patients in our current trial to the
levels reported in the large randomized trial from
Overgaard et al. [14], we observed that all our patients
should be assigned to the low or intermediate concentra-
tions of plasma osteopontin. Also, in comparison to a
study in 295 patients with advanced rectal cancer, our
observed levels of osteopontin and CAIX were lower than
their reported average values [29]. In addition, plasma
osteopontin is not only influenced by hypoxia, it is also
known to play a role in the immune regulation and stress
response [30]. An elevated level of osteopontin was for
example observed in patients with systemic inflammatory
response syndrome or sepsis [31]. The given anti-cancer
treatment might have induced an immune/stress response
causing an elevated level of osteopontin. The observed
concentration of plasma CAIX (190 ± 120 pg/ml) was
higher than documented for 209 patients with NSCLC
(mean: 45 pg/ml) or 58 healthy individuals (mean:
2.5 pg/ml) [15]. The concentration of plasma VEGF (85
± 67 pg/ml) was similar to that observed in patients with
NSCLC [32] and higher than reported in 50 healthy wom-
en (median: 37 pg/mL [33]). Nevertheless, in the current
population the blood biomarkers osteopontin, CAIX, and
VEGF were not suitable to measure a hypoxia-related
treatment response, which was measurable using
[18F]HX4-PET.
The correlation between the blood hypoxia markers and the
[18F]HX4 PET uptake was absent to weakly present. This was
Fig. 3 Spatial reproducibility of the [18F]HX4 PET uptake in two
patients with persistent hypoxia during treatment (left: patient with
cT2N2aM0 hypopharynx cancer, right: patient with cT2N2bM0
oropharynx cancer. The PET-CT scans during treatment were in both
patients performed after 18 Gy. Visualised is the voxel-wise correlation
of the [18F]HX4-uptake within the GTV
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in agreement with the results previously published by several
groups comparing hypoxia PET imaging to tissue or blood
markers. Vercellino et al. [34] observed no correlation be-
tween the uptake of the hypoxia tracer [18F]FETNIM and
the plasma osteopontin concentration in 16 patients with cer-
vical carcinoma. In addition, Gronroos et al. [35] found no
correlation between hypoxia PET imaging using FETNIM
and several tissue biomarkers in 15 patients with HNSCC.
While in patients with newly diagnosed glioma, the preoper-
ative [18F]FMISO PET uptake was significantly, but weakly,
correlated to the expression of VEGF in the tumour [36].
Although the current patient population is small, the results
suggest that the tested blood biomarkers are not able to replace
hypoxia PET imaging, or to pre-select patients for hypoxia
PET imaging.
To conclude, hypoxia PET imaging with [18F]HX4 is
able to detect tumour hypoxia in patients with HNSCC;
in addition, it can monitor a decrease of tumour hypoxia
during treatment. In patients with persistent tumour hyp-
oxia, a stable localization of the hypoxic volume was
observed. This provides potential for radiotherapy dose
escalation to the hypoxic volumes. The blood parame-
ters osteopontin, CAIX, and VEGF were not able to
detect a decrease in hypoxia during treatment. In addi-
tion, there was no correlation between the blood plasma
parameters CAIX and VEGF and hypoxia PET imaging,
while only a weak correlation was observed between
[18F]HX4 PET imaging and the osteopontin concentra-
tion during treatment. Based on the current data, we
conclude that hypoxia PET imaging is the superior
method to evaluate tumour hypoxia before and during
treatment and cannot be replaced with the evaluated
blood biomarkers.
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